Can a scope in the stomach measure hidden liver pressure?

NCT ID NCT07782554

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study looks at whether a new endoscopic ultrasound technique can directly measure the pressure in the portal vein, which carries blood to the liver. It focuses on people with cirrhosis who also have a blockage in the portal vein, a condition where standard pressure measurements may be inaccurate. Researchers will compare the new method's readings with the traditional approach and see how they relate to patient symptoms and outcomes. The goal is to see if this technique could provide a more reliable way to assess and manage this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endoscopic ultrasound-guided portal pressure gradient measurement (EUS-PPG)
What this could lead to
If EUS-PPG proves reliable, it could offer a more accurate way to assess portal hypertension in patients where standard methods fall short, potentially guiding better treatment decisions.
What could go wrong
This is a small, retrospective study, so results may not apply broadly. The procedure is invasive and carries risks like bleeding or infection, and the correlation with standard measures may not be strong enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

59 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study included patients with liver cirrhosis complicated by prehepatic portal hypertension due to portal venous obstruction. All patients had esophagogastric varices and underwent abdominal computed tomography, ultrasound elastography, hepatic venous pressure gradient measurement, and endoscopic ultrasound-guided portal pressure gradient measurement. The study evaluated the relationship between portal pressure measurements and clinical characteristics, including liver disease etiology, liver function grade, gastrointestinal bleeding, and hepatic encephalopathy.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥18 years; Confirmed diagnosis of cirrhosis complicated by portal venous obstructionbased on clinical, laboratory, and imaging findings; Written informed consent; Exclusion Criteria: Severe coagulopathy, defined as an International Normalized Ratio (INR) \>1.5; Severe thrombocytopenia, defined as a platelet count \<30 × 10\^9/L; Severe systemic comorbidities, including active sepsis, decompensated heart failure, or severe chronic obstructive pulmonary disease; Psychiatric or cognitive disorders that preclude cooperation with study procedures; Refusal to undergo hepatic venous pressure gradient (HVPG) or endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prehepatic portal hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310009, China